secwatch.observer — SEC 8-K summary
======================================

Issuer:     GridAI Technologies Corp. (GRDX)
CIK:        0001604191
Form:       8-K/A
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001104659-24-066738
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entero Therapeutics files Q1 2024 pro forma statements post-ImmunogenX merger
-----------------------------------------------------------------------------

- Amendment adds unaudited pro forma combined statement of operations for three months ended March 31, 2024.
- Pro forma combined net loss applicable to common shareholders: $1,894,119.
- Pro forma basic loss per share: $1.08; diluted loss per share: $1.08.
- Merger with ImmunogenX closed March 13, 2024; Entero is accounting acquirer.
- No changes to merger terms or business operations; filing purely supplemental.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924066738/0001104659-24-066738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924066738/tm2416013d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-066738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer